Managed-care insurers sit at the center of U.S. healthcare spending, and few comparisons capture the sector's current dynamics better than CNC versus ELV. Centene is the nation's largest Medicaid-focused insurer and a classic turnaround story, while Elevance Health is a diversified, dividend-paying giant built on commercial coverage and its Carelon services arm. Traders drawn to momentum and value may gravitate toward Centene's recovery, whereas investors prioritizing stability and income often look to Elevance. This stock comparison examines business models, recent market activity, and relative positioning to clarify how these two names measure up in today's environment. I also checked sector peers using Tickeron’s AI Screener to put the contrast in context.
Centene Corporation is a St. Louis-based managed-care company serving roughly 24 million members, with a heavy emphasis on Medicaid, Medicare, and the Affordable Care Act (ACA) Marketplace. It is a low-margin, high-volume business: recent quarters show a health benefits ratio near 92.7%, meaning about 93 cents of every premium dollar goes to medical care.
Over the past year, CNC has been one of the strongest performers in its sector, roughly doubling in value as investors bet on a margin recovery following a difficult 2025. Recent third-quarter results reinforced that narrative, with adjusted EPS of $0.58 far exceeding consensus and full-year guidance raised above $5.20. However, the stock has shown elevated volatility, pulling back after strong runs as markets questioned whether the recovery is sustainable. Declining Medicaid and Marketplace membership, rising provider-dispute reserves, and an operating loss in the latest quarter highlight that the turnaround is not yet complete. From what I see, the momentum remains real but needs more confirmation on execution.
Elevance Health, formerly Anthem, is one of the largest U.S. health insurers, serving about 45 million medical members and operating as the largest single licensee of Blue Cross Blue Shield across 14 states. Its portfolio is more balanced than Centene's, combining commercial employer coverage, government programs, and Carelon—a fast-growing pharmacy and healthcare services business.
In recent weeks, ELV has advanced steadily, supported by third-quarter results that beat expectations, with adjusted EPS of $6.99 versus a roughly $4.70 consensus. Management raised 2026 adjusted EPS guidance to at least $29.00 and reiterated expectations for at least 12% growth in 2027. The benefit expense ratio improved to 90.6%, and Carelon delivered a 17% rise in operating gain. While Medicaid margins remain below target and total membership has declined modestly, Elevance's diversified model and dividend provide a steadier, lower-volatility profile than Centene's concentrated turnaround. I reviewed the earnings trend using Tickeron’s AI Trend Prediction Engine to see how the steadier path compares.
The clearest contrast is diversification versus concentration. CNC derives the bulk of its premiums from government programs, making it highly sensitive to Medicaid rate resets and policy changes, whereas ELV spreads risk across commercial, government, and services revenue.
On valuation, CNC trades at a discount relative to its earnings guidance—a reflection of its thinner, less predictable margins—while ELV commands a higher multiple backed by steadier profitability and a dividend. Momentum favors Centene, but consistency and balance-sheet quality favor Elevance. Risk factors differ too: Centene faces membership attrition and margin-repair execution risk, while Elevance carries elevated Medicaid cost trends and regulatory exposure. In short, CNC offers higher potential reward with greater volatility, and ELV offers more predictable, diversified earnings.
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would currently lean toward ELV. Elevance Health's steadier trend, diversified earnings base, improved benefit expense ratio, and clear 2027 growth outlook provide a more durable foundation than Centene's higher-momentum but still-repairing margin story. While CNC's turnaround could continue to reward momentum-oriented traders, its recent pullbacks and GAAP losses introduce greater uncertainty. The AI's preference is therefore probabilistic rather than definitive: Elevance Health appears better positioned on stability and consistency, while Centene remains the higher-beta option for those focused on momentum.
When analyzing stocks like these, I sometimes review Tickeron’s Trending AI Robots to see which automated strategies align with current market conditions. The platform highlights bots with different styles, timeframes, and performance records, offering a practical way to complement manual research without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CNC moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 56 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on CNC as a result. In 59 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The 10-day moving average for CNC crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNC advanced for three days, in 186 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 132 of 213 cases where CNC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The 10-day RSI Indicator for CNC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 19 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 60 cases where CNC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for CNC turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
CNC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 12 (best 1 - 100 worst), indicating outstanding price growth. CNC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CNC's P/B Ratio (1.527) is slightly lower than the industry average of (3.520). P/E Ratio (-6.751) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.160) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a multi-line healthcare enterprise
Industry ManagedHealthCare